The Immune-Mediated Inflammatory Diseases Market Size is estimated to grow at a 7.10% CAGR during the forecast period for 2024-2031.
Immune-mediated inflammatory disease (IMID) is refered as a collection of unrelated illnesses that have a common inflammatory pathway that causes inflammation but no clear etiology. Immune-mediated inflammatory diseases are disorders brought on by the immune system's excessive or aberrant activity. All immune-mediated inflammatory disorders (IMID) are linked to higher rates of morbidity and/or mortality, as well as the potential to harm organs. Worldwide, the number of people afflicted with autoimmune illnesses is steadily increasing. Many of these illnesses have underlying causes that might be linked to genetic predispositions, unhealthy eating patterns, and poor lifestyle choices. The market for immune-mediated inflammatory diseases is growing globally as the prevalence of these illnesses rises.
The need for immune-mediated inflammatory disease treatment has increased due to an increase in the frequency of chronic diseases of the liver, heart, kidneys, pancreas, and blood problems. The global market for immune-mediated inflammatory diseases is, therefore, driven by an increase in the prevalence of autoimmune diseases worldwide. However, during the projected time, it is expected that inadequate reimbursement, pharmacological side effects, and a lack of patient awareness will impede immune-mediated inflammatory disease market expansion.
Competitive Landscape
Some Major Key Players In The Immune-Mediated Inflammatory Diseases Market:
- Novartis AG
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
- Abbvie Inc.
- Merck & Co Inc.
- Zydus Group
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- AstraZeneca
- Ampio Pharmaceuticals Inc.
- Eli Lilly
- Akorn Incorporated
- Other Market Players
Market Segmentation:
The immune-mediated inflammatory diseases market is segmented based on indication, treatment type, indication, route of administration, end-user, and distribution channel. The indication segment is further segmented into Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Psoriasis, Rheumatoid Arthritis (RA), and Others. By treatment type, the market is segmented into Traditional Drugs, Biologic Therapies, and Novel Therapies. The route of administration segment includes Oral, Parenteral, and Others. As per the end-user, the market is segmented into Hospitals, Specialty Clinics, and Others. According to the distribution channel segment, the market is divided into Hospital Pharmacy, Retail Pharmacy, and Others.
Based On The Indication, The Rheumatoid Arthritis (RA) Segment Is Accounted As A Major Contributor To The Immune-Mediated Inflammatory Diseases Market
The Rheumatoid Arthritis (RA) category is expected to lead with a significant market share, driven by improvements in targeted biologic therapy, growing prevalence rates, and growing awareness of early detection. The management of RA has changed as a result of the increasing use of biologics and disease-modifying antirheumatic medications (DMARDs), such as TNF inhibitors and interleukin blockers, which have improved patient outcomes. In order to meet unmet clinical needs, pharmaceutical companies are also concentrating on creating novel medicines, such as Janus kinase (JAK) inhibitors. Further driving market expansion includes the rising prevalence of RA, particularly in older populations, and supportive healthcare policies.
Hospitals Segment To Witness Growth At A Rapid Rate.
The hospitals held the largest share in the immune-mediated inflammatory diseases market. Hospitals are treating more patients with immune-mediated inflammatory diseases. A range of autoimmune disorders are treated using the medicines. The disease is effectively controlled by the medicines, and its advancement is halted. Furthermore, the therapies aid in enhancing the patients' quality of life.
In The Region, The North American Immune-Mediated Inflammatory Diseases Market Holds A Significant Revenue Share.
The North American immune-mediated inflammatory diseases market is expected to note the highest market share in revenue in the near future due to the region's concentration of significant pharmaceutical companies and rising healthcare costs. The demand for novel treatments, the rising prevalence of autoimmune diseases, and the growing significance of targeted biologic therapy are all driving forces behind the immune-mediated inflammatory diseases market's growth. The market is also expected to be driven by the increasing number of novel therapeutic approvals and the rising demand for immunosuppressants in North America. In addition, Asia Pacific is predicted to grow rapidly in the global immune-mediated inflammatory diseases market as a result of increased awareness and information about this area. The immune-mediated inflammatory diseases market's expansion in this sector is also being fueled by more treatment options becoming available, an increase in the frequency of autoimmune diseases, and technological advancements in the management of immune-mediated inflammatory diseases.
Recent Developments:
- In July 2024, AbbVie announced that the European Commission has sanctioned SKYRIZI® (risankizumab) for the treatment of elderly individuals with moderately to severely active ulcerative colitis (UC) who have experienced an inadequate response to, lost response to, or exhibited intolerance to conventional or biologic therapies.
Immune-Mediated Inflammatory Diseases Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 7.10% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Indication, Treatment Type, Indication, Route Of Administration, End-User, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Merck & Co Inc. (U.S.), Zydus Group (India), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S), and Akorn, Incorporated (U.S.). |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
